No Fed urgency leaves stocks at risk: JPMorgan

  • 📰 Investingcom
  • ⏱ Reading Time:
  • 44 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 21%
  • Publisher: 53%

Россия Новости Новости

Россия Последние новости,Россия Последние новости

No Fed urgency leaves stocks at risk: JPMorgan

JPMorgan analysts have raised concerns that the current equity market is increasingly a"two-sided debate," with risks stemming from potential growth downturns, uncertain Fed timing, and various geopolitical factors.

The bank explains that in the first half of the year, market attention was largely focused on the trajectory of inflation. However, the second half of the year is shifting attention to growth risks, particularly given the elevated earnings expectations for the latter half of 2024 and for 2025 . The current market pullback is seen as a reaction to fears of weakening growth and a reassessment of recession probabilities.

However, they conclude:"While the recent market flush took out some of the froth, equity positioning and valuation still remain at risk especially if growth continues to decelerate and the Fed does not show urgency."Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors.

 

Спасибо за ваш комментарий. Ваш комментарий будет опубликован после проверки
Мы обобщили эту новость, чтобы вы могли ее быстро прочитать.Если новость вам интересна, вы можете прочитать полный текст здесь Прочитайте больше:

 /  🏆 450. in RU

Россия Последние новости, Россия Последние новости

Similar News:Вы также можете прочитать подобные новости, которые мы собрали из других источников новостей

JPMorgan stock price at record high ahead of Q2 earningsJPMorgan earnings kick off earnings season on 12 July, but a slowdown is expected despite the stock’s run to record highs.
Источник: DailyFX - 🏆 305. / 63 Прочитайте больше »

Here are JPMorgan's top drug stock picks into earningsThese are JPMorgan's top drug picks heading into earnings.
Источник: CNBC - 🏆 12. / 72 Прочитайте больше »